Immunai
Reprogramming the Immune System to Improve Health
Hybrid
Some members of the team work remotely, while others are co-located in one or more offices.
👥51-200
📍New York, NY
Immunai
About Immunai
Comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
What Immunai is building
A biotech company that combines single cell genomics with ML algorithms to enable high resolution profiling of the immune system.
Technologies used at Immunai
Back-end (3)
Python
R
AWSFunding rounds
Total Funding
$295M
Last funding round type
Series B
Company type
For Profit
Immunai news and updates
8 VC invests into Immunai in $215M
Immunai has raised $215 million in Series B funding led by Koch Disruptive Technologies, with participation from Talos VC, 8VC, Alexandria Venture Investments, Piedmont, ICON and others.
Jan 1, 2021 | vator.tvViola group invested into Immunai Inc. in $20M on Nov 8th 18'.
I’ve been seeing a lot of press lately about a new US/Israeli startup called Immunai, which recently raised a $20 million seed round led by Viola Ventures and TLV Partners.
Jan 1, 2018 | entis-ip.comViola group invested into Immunai Inc. in $20M on May 28th 20'.
Biotech company Immunai announced on Thursday that it had completed a $20 million seed round led by Viola Ventures and TLV Partners.
Jan 1, 2020 | calcalistech.com